The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 58 of the 80 sources its claims cite were checked for support.
Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency
Open accessAbstract
Background mRNA vaccines hold great potential as therapeutic techniques against viral infections due to their efficacy, safety, and large-scale production. mRNA vaccines offer flexibility in development as any protein can be produced from mRNA without altering the production or application process.Objective This review highlights the iterative optimization of mRNA vaccine structural elements that impact the type, specificity, and intensity of immune responses leading to higher translational potency and intracellular stability.Results Modifying the mRNA structural elements particularly the 5' cap, 5'-and 3'-untranslated regions (UTRs), the coding region, and polyadenylation tail help reduce the excessive mRNA immunogenicity and consistently improve its intracellular stability and translational efficiency.Conclusion Further studies regarding mRNA-structural elements and their optimization are needed to create new opportunities for engineering mRNA vaccines.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This narrative review summarizes how iterative optimization of mRNA vaccine structural elements—the 5′ cap, 5′- and 3′-UTRs, the coding region (ORF), and the poly(A) tail—can reduce excessive mRNA immunogenicity while improving intracellular stability and translational efficiency. It frames these modifications as the basis for the rapid development and >90% efficacy of the BNT162b2 and mRNA-1273 COVID-19 vaccines.
Key findings
- Modifying mRNA structural elements (5′ cap, 5′- and 3′-UTRs, coding region, poly(A) tail) reduces excessive mRNA immunogenicity and consistently improves intracellular stability and translational efficiency.
- Higher GC content translates 100-fold higher than a low GC sequence, though high GC can cause problems for mRNA secondary structure; codon optimization affects translation efficiency, mRNA abundance, and protein folding.
- Nucleoside modification lowers immunogenicity while increasing translation: Kormann et al. reported that 2 weeks after injection of mRNA containing 25% thio-uridine and 25% 5-methylcytidine, Epo levels were five times greater than in untreated animals, whereas unmodified mRNA showed no significant alterations and elicited a considerable immunological response.
- ARCA-capped mRNA showed translation efficiency twice that of mRNA capped by a conventional cap analog in rabbit reticulocyte lysate, and had a longer half-life in cultured cells; poly(A) tails of approximately 100 nt are described as ideal for mRNA therapeutics (mammalian cell mRNAs carry ~250 nt tails).
- BNT162b2 and mRNA-1273 both use N1-methylpseudouridine (1mΨ) modification and dsRNA fragment removal; both encode spike proteins with K986P and V987P substitutions, and both have efficacy above 90% (~95%).
Methods
- Design: narrative review of mRNA vaccine structural element design and modification, drawing on cited primary literature rather than presenting new experimental data.
- Scope: covers the ORF, 5′- and 3′-UTRs, 5′ capping, the poly(A) tail, immunogenicity elimination, advantages of mRNA vaccines, and the COVID-19 mRNA vaccines BNT162b2 and mRNA-1273.
- Main analysis: qualitative synthesis organized around each structural element, with a summary table (Table 1) mapping each element's modification to its effect (e.g., UTR length/structure → modulate translation efficiency; cap structure → increase protein synthesis and stability; codon optimization → enhance protein expression; poly(A) tail elongation → increase stability and translational efficiency).
Limitations
- Stated in the paper: the most difficult task needing attention is striking a balance between translation efficiency and immune response to provide appropriate and safe immunogenicity; further studies on mRNA structural elements and their optimization are needed.
- Stated in the paper: despite the advantages of mRNA vaccines, many risks remain—long-term effects of mRNA vaccines are unknown, and mRNA is unstable and must be stored at high temperature, making packaging and distribution difficult (the paper also notes cold-chain storage/transport as a major technical and financial challenge).
- Evident from the text: as a narrative review, it presents no primary data, systematic search strategy, or quantitative synthesis; several cited findings are attributed to other studies, and Moderna's structural elements are described as undisclosed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
26 No basis given · 24 Own interpretation · 22 Partly supported · 19 Supported · 11 No full text of the sources · 5 Couldn’t confirm · 4 Supported so far · 4 Sources not found · 2 Not supported · 1 Not checked yet · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Although high GC-content may cause problems for mRNA secondary structure, the higher GC sequence translates 100-fold higher than a low GC sequence (Kudla et al. 2006).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Disputedcites Kudla et al. 2006 sourceExperimental — accuracy not yet measured
The Results (page unavailable) attribute higher protein output from GC-rich GFP to higher mRNA levels, not a higher translation rate. The Discussion likewise says codon optimization increased GFP mRNA levels rather than its translation rate. The claimed 100-fold increase in translation is therefore contrary to the paper's finding. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Codon composition is known to influence translation efficiency.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Disputedcites Kudla et al. 2006 sourceExperimental — accuracy not yet measured
The Discussion says a translational explanation for codon-optimization effects had often been assumed but not thoroughly tested; it attributes most observed effects in mammalian cells to changes in mRNA levels instead. The Results found no detectable difference in translation rates between two genes with different proportions of preferred codons. The paper therefore does not present an effect on translation efficiency as established. (LLM, conf=0.79)
Checked by a reasoning model — may be wrong.
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
What the sources say
- Supportedcites Sahin et al. 2014 source
The “5′- and 3′-UTRs” section says that many IVT mRNAs contain α- and β-globin 3′ UTRs and that these UTRs harbour sequence elements increasing mRNA stability and translation. This directly supports the attributed claim. (LLM, conf=0.95)
- Not checked — no full text of the sourcecites Karikó et al. 1999 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The modified nucleosides escape the type interferons (IFNs) induced antiviral pathways and are targeted to break and block invading mRNA; therefore they can be used to create mRNA vaccines with significantly improved translation efficiency (Verbeke et al. 2019).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Supportedcites Verbeke et al. 2019 source
Section 2.3 (page not provided) states that incorporating modified nucleosides can give mRNA vaccines strongly enhanced translation capacity by avoiding type IFN-induced antiviral pathways. It says those pathways, rather than the modified nucleosides, are programmed to degrade and inhibit invading mRNA. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Substituting rare codons with identical frequent codons boosts yield as reusing same tRNA speeds up translation due to amino-acylation of tRNAs near ribosomes (Cannarozzi et al. 2010).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Partly supportedcites Cannarozzi et al. 2010 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that replacing rare codons with frequent synonymous codons improves translation efficiency. The Results and Discussion (pages unavailable) separately link faster translation to reusing the same tRNA through codon order, not to that replacement; the Discussion treats retention of tRNAs near ribosomes as a proposed mechanism. The source therefore supports the yield claim but not the sentence’s asserted causal link. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The translation elongation rate is controlled by the accessibility of cognate tRNA species and the codon usage modification to prevent the match rare tRNA sequence of species and integrate sequences that match more common tRNA species (Hanson and Coller 2018).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Supportedcites Hanson and Coller 2018 source
In “Codons affect translation elongation” (page unavailable), the review says elongation depends on the tRNA pool because ribosomes wait longer for rare cognate tRNAs. It also reports faster translation of codon-optimized mRNAs than non-optimized mRNAs, supporting the claim that codon usage can be modified to affect elongation rate. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Screening mRNA against exonuclease activity, promoting pre-mRNA splicing, and functioning as binding site of eIF4F heterodimeric translation initiation complex are all important functions of 5′-capping (Izaurralde et al. 1994; Gallie 1991).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
What the sources say
- Not checked — no full text of the sourcecites Izaurralde et al. 1994 source
- Could not verifycites Gallie 1991 sourceExperimental — accuracy not yet measured
The paper’s opening discussion and Discussion section address the cap’s roles in translation and mRNA stability, not pre-mRNA splicing. Searches for splicing and for cap-dependent removal of introns found no passage stating that capping promotes splicing; a splicing study appears only in the References. (LLM, conf=0.75)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The 5′-cap structure is a key factor in the host's ability to differentiate between self and non-self mRNA molecules (Devarkar et al. 2016).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
What the sources say
- Supportedcites Devarkar et al. 2016 source
The paper explains that modifications at the 5′ end of cellular mRNAs help RIG-I distinguish self from nonself RNA (p. 1). Its Results and Discussion (p. 5) identify the 2′-O-methylation in Cap-1 as essential for avoiding RIG-I recognition; the m7G Cap-0 structure alone does not prevent recognition. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The structural characteristics of mRNA such as the CAP, poly(A) tail, and untranslated regions (UTRs) directly impact mRNA stability and translation efficiency (Orlandini von Niessen et al. 2019; Holtkamp et al. 2006).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Not checked yetcites Orlandini von Niessen et al. 2019 source
Checked before — its earlier verdict is held back until a new check runs.
- Supportedcites Holtkamp et al. 2006 source
The Discussion states that the poly(A) tail regulates mRNA fate in synergy with the 5′ cap and that 3′ UTR changes improve translational characteristics. The results section on combined modifications reports improved RNA stability and sustained protein expression. The paper thus supports the broad claim about these structural features, although it did not separately test the cap. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not checked yet
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“(iii) Shorter 5′UTRs may be used, as past research has indicated that this type of 5′UTR is better for mRNA translation (Leppek et al. 2018).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
What the sources say
- Could not verifycites Leppek et al. 2018 sourceExperimental — accuracy not yet measured
The section ‘5′ UTRs as platforms for RNA structure’ describes variation in UTR length but does not compare translation efficiency by length. ‘5′ UTR structures in ribosome scanning’ notes that some exceptionally short UTRs permit scanning-free initiation; it does not say shorter UTRs are generally better for translation. Searches for short UTRs and translational efficiency found no such comparison in our copy. (LLM, conf=0.70)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Deleting the poly(A) region from mRNA results in mRNA being unstable compared to the intact gene (Whitelaw et al. 1986).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Partly supportedcites Whitelaw et al. 1986 sourceExperimental — accuracy not yet measured
The Abstract reports that deleting the poly(A) site from the human α-globin gene produces very little stable mRNA compared with the intact gene. It describes mRNA instability as the presumed explanation, not a demonstrated result. The claim also omits that this finding concerns the α-globin gene’s poly(A) site rather than deletion of a region from mRNA itself. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
What the sources say
- Supportedcites Sahin et al. 2014 source
The “5ʹ-and 3ʹ-UTRs” section states that many IVT mRNAs contain the 3ʹ-UTRs of α- and β-globin mRNAs. It also says these UTRs harbour sequence elements that increase mRNA stability and translation. (LLM, conf=0.95)
- Not checked — no full text of the sourcecites Karikó et al. 1999 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The steady effect of human β-globin 3ʹ-UTR sequences is enhanced when two human β-globin 3ʹ-UTRs are placed in a head-to-tail orientation (Holtkamp et al. 2006).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
What the sources say
- Supportedcites Holtkamp et al. 2006 source
The Results section on tandem β-globin 3′ UTRs says that two human β-globin 3′ UTRs fused head to tail produced higher protein levels and longer protein persistence than a single UTR. The Discussion explicitly says two serial UTRs were better than one at improving RNA translational characteristics. The paper does not use the phrase “steady effect,” but it supports the stabilizing effect described. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The poly(A) tail steadies mRNA and boosts protein translation, and the length of the poly(A) tail is proportional to translation efficiency.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > The poly(A) tail
What the sources say
- Partly supportedcites Park et al. 2016 sourceExperimental — accuracy not yet measured
In “Translational Regulation and Poly(A) Tail Control during the Somatic Cell Cycle” (Figure 3B), the paper reports a relationship between tail length and translation efficiency only for short tails, up to about 20 nt. It says lengthening beyond that does not further influence translation, so the unqualified claim of proportionality overstates the finding. (LLM, conf=0.90)
- Partly supportedcites Jalkanen et al. 2014 sourceExperimental — accuracy not yet measured
The Introduction says poly(A) tails can enhance translation efficiency. But “Does size matter?” reports a relationship between tail length and translation in early development and certain other contexts, while noting that a global analysis found no significant correlation beyond embryonic stages. The source therefore does not support an unqualified, proportional relationship. (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, mRNA secondary structure design can be modified to improve mRNA stability against endonuclease cleavage and chemical degradation (Wayment-Steele et al. 2021).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Supportedcites Wayment-Steele et al. 2021 source
The Introduction says that increasing mRNA secondary structure can reduce hydrolysis. The Results section, “A biophysical model for RNA degradation,” says the framework also applies to degradation suppressed by RNA structure, including digestion by endonucleases. The paper presents this improvement as a computational prediction, not an experimentally demonstrated increase in stability. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Screening mRNA against exonuclease activity, promoting pre-mRNA splicing, and functioning as binding site of eIF4F heterodimeric translation initiation complex are all important functions of 5′-capping (Izaurralde et al. 1994; Gallie 1991).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
What the sources say
- Not checked — no full text of the sourcecites Izaurralde et al. 1994 source
- Supportedcites Gallie 1991 source
The Discussion reports that a cap increased mRNA stability two- to fourfold. The section on translational efficiency in tobacco also describes loss of the cap through exonuclease attack, supporting the paraphrase that capping protects mRNA against such activity. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, the rate of codon-dependent translation elongation has been a primary factor of mRNA stability, codon modification is critical for mRNA stability (Presnyak et al. 2015).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Supportedcites Presnyak et al. 2015 source
The Results section, “Optimal codon content directly influences mRNA decay rate,” reports that changing codon composition altered mRNA decay and calls optimal codon content a critical determinant of stability. The Introduction also links codon-dependent translation elongation to mRNA stability. These passages support the citing sentence’s point about codon modification. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, the rate of codon-dependent translation elongation has been a primary factor of mRNA stability, codon modification is critical for mRNA stability (Presnyak et al. 2015).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Supportedcites Presnyak et al. 2015 source
The Introduction states that codon-dependent translation elongation rate is an important determinant of mRNA stability. The Discussion reports that changing codons altered mRNA stability and provides evidence that the effect operates through translation elongation rates; the experiments described were in budding yeast. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, mRNA transcribed in vitro using ARCA has been found to have a longer half-life in cultivated cells (Grudzien et al. 2006).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
What the sources say
- Supportedcites Grudzien et al. 2006 source
The Results report longer half-lives for ARCA-capped luciferase mRNA than for conventionally capped mRNA with both tested poly(A) lengths (282 versus 156 minutes and 90 versus 60 minutes). The in vivo measurement methods describe introducing the RNA into cultured MM3MG cells and measuring its stability there. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The 5′- and 3′- UTRs comprising of regulatory sequence elements are known to regulate the mRNA stability.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
What the sources say
- Partly supportedcites Tanguay and Gallie 1996 sourceExperimental — accuracy not yet measured
The paper’s introductory section says that 3′ UTRs can regulate mRNA stability, and the Results report increased stability when the 3′ UTR was lengthened in nonpolyadenylated reporter mRNA. The passages do not establish that 5′ UTRs regulate stability; this study also attributes its measured 3′ UTR effect primarily to length rather than regulatory sequence. Page numbers are unavailable in our copy. (LLM, conf=0.88)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Screening mRNA against exonuclease activity, promoting pre-mRNA splicing, and functioning as binding site of eIF4F heterodimeric translation initiation complex are all important functions of 5′-capping (Izaurralde et al. 1994; Gallie 1991).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
What the sources say
- Not checked — no full text of the sourcecites Izaurralde et al. 1994 source
- Partly supportedcites Gallie 1991 sourceExperimental — accuracy not yet measured
The Discussion (page not provided) identifies the 5′ cap as a recognition site for eIF-4E, a subunit of eIF-4F, and says eIF-4F binds the cap. It does not describe eIF-4F as heterodimeric, so that structural detail is unsupported by our copy. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“It is a critical factor in determining the longevity of mRNA molecules (Park et al. 2016; Jalkanen et al. 2014).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > The poly(A) tail
What the sources say
- Supportedcites Park et al. 2016 source
The Abstract states that poly(A) tails are critical for mRNA stability, which supports the claim about mRNA longevity. The Introduction also describes the poly(A) tail as important for mRNA stability. (LLM, conf=0.91)
- Supportedcites Jalkanen et al. 2014 source
The Introduction says poly(A) tails are vital for regulating mRNA degradation and that tail shortening is a key step initiating decay. The “Does size matter?” section also describes how changes in tail size can signal mRNA degradation. Together, these support the claim that the poly(A) tail is important to mRNA longevity. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Furthermore, increasing the G-C fraction of mRNA improves mRNA stability (Homma et al. 2016).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Could not verifycites Homma et al. 2016 sourceExperimental — accuracy not yet measured
The Introduction and Discussion address codon usage, translation speed, and translational accuracy, not mRNA stability. Searches for increased G-C fraction, GC content, and mRNA stability found no passage in our copy supporting the claimed effect. (LLM, conf=0.76)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The poly(A) tail is important for mRNA stability and translation success (Kudla et al. 2006).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Could not verifycites Kudla et al. 2006 sourceExperimental — accuracy not yet measured
The Discussion links GC content to the production of polyadenylated mRNA and examines mRNA stability, but does not say that the poly(A) tail is important for stability or translation. Searches for “poly(A) tail,” “polyadenylation translation efficiency,” and “poly(A)” found no passage making that claim; the reference list alone does not establish it. (LLM, conf=0.74)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, with the advancement of lipid nanoparticle techniques, mRNA vaccine stability can be maintained under less rigorous settings (Reichmuth et al. 2016).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
What the sources say
- Partly supportedcites Reichmuth et al. 2016 sourceExperimental — accuracy not yet measured
The executive summary (page unavailable) says lipid nanoparticles protect mRNA against degradation, supporting the stability aspect. The paper discusses instability under physiological conditions but does not say that LNP-formulated vaccines remain stable under less rigorous storage or handling conditions. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Eliminating mRNA immunogenicity
What the sources say
- Partly supportedcites Sahin et al. 2014 sourceExperimental — accuracy not yet measured
The “Immune-stimulatory activity of IVT mRNA” section calls innate immune activation a major disadvantage for protein-replacement therapies, but an added benefit for vaccination. It does not identify immunogenicity as the most challenging obstacle for mRNA generally; the “Progress in improving mRNA delivery” section also describes substantial delivery challenges. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reduced efficacy of protein expression produced by high GC concentration needs to be addressed (Wang et al. 2021).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Eliminating mRNA immunogenicity
What the sources say
- Supportedcites Wang et al. 2021 source
In “Eliminating immunogenicity of mRNA,” the paper explicitly warns that excessive GC content can cause low efficacy of protein expression. This supports the citing sentence’s point about high GC concentration. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“BNT162b2 (BioNTech/Pfizer) and mRNA-1273 (Moderna) used a mixture of altered nucleotide 1mΨ modifications and dsRNA fragment eviction in the mRNA manufacturing procedure to significantly lower innate immune signaling in response to mRNA (Walsh et al. 2020; Jackson et al. 2020b).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
What the sources say
- Partly supportedcites Walsh et al. 2020 sourceExperimental — accuracy not yet measured
The Introduction identifies BNT162b2 as a nucleoside-modified RNA vaccine, and the Discussion says it shares an RNA production and purification process with BNT162b1. Neither section specifies 1mΨ modification or dsRNA-fragment removal, demonstrates a significant reduction in innate immune signaling from those steps, or describes mRNA-1273’s manufacturing process. (LLM, conf=0.84)
- Partly supportedcites Jackson et al. 2020b sourceExperimental — accuracy not yet measured
The Discussion says mRNA-1273 uses modified nucleotides that avoid early activation of interferon-associated genes, supporting the general point about reduced innate immune signaling. It does not identify the modification as 1mΨ, describe dsRNA-fragment removal during manufacture, or address BNT162b2; the Methods > Vaccine section likewise describes mRNA-1273 without those manufacturing details. No page numbers are available in our copy. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“mRNA vaccines must be stored and carried at extremely low temperatures as compared to protein-based vaccinations that can be stored and transported at lower temperatures (Crommelin et al. 2020).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
What the sources say
- Partly supportedcites Crommelin et al. 2020 sourceExperimental — accuracy not yet measured
The Introduction describes mRNA vaccine candidates kept at −80 °C and the difficulty of transporting them under those conditions. The storage-conditions table lists frozen storage for three COVID-19 mRNA candidates, but also limited periods at 2–8 °C; the claim's unqualified “must” is too broad. Our copy does not provide the asserted comparison with protein-based vaccines. (LLM, conf=0.87)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The insertion of modified nucleotides into the poly(A) tail by recombinant poly(A) polymerase inhibits deadenylation by poly(A)-specific nucleases (Korner and Wahle 1997).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > The poly(A) tail
What the sources say
- Partly supportedcites Korner and Wahle 1997 sourceExperimental — accuracy not yet measured
The RNA Decay Assays section (page unavailable) reports that DAN did not degrade poly(A) with a phosphorylated 3′ end, supporting the narrower point that a terminal modification can block this nuclease. The Experimental Procedures section describes recombinant yeast poly(A) polymerase, but does not report that it inserted modified nucleotides or that such insertion inhibited deadenylation by poly(A)-specific nucleases generally. (LLM, conf=0.85)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Therefore, immunizing against the full S protein rather than just one of its structural units may lead to a better response that is not impacted by genetic drift (Liu et al. 2020).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
What the sources say
- Partly supportedcites Liu et al. 2020 sourceExperimental — accuracy not yet measured
The Discussion (p. 6) says that vaccine strategies omitting the NTD cannot induce an important class of neutralizing antibodies, supporting the rationale for including more than one spike region. But the paper does not compare immune responses to full-spike and single-unit immunization or establish that a full-spike response would be unaffected by genetic drift (searched: “genetic drift” and viral escape). (LLM, conf=0.88)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The 5′ cap regulates pre-mRNA splicing and nuclear export, works as a protective structure that shields RNA from exonuclease cleavage, and initiates mRNA translation.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Modifying the mRNA structural elements particularly the 5′ cap, 5′-and 3′-untranslated regions (UTRs), the coding region, and polyadenylation tail help reduce the excessive mRNA immunogenicity and consistently improve its intracellular stability and translational efficiency.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Abstract > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“When ARCA-capped mRNA was compared to mRNA capped by a conventional cap analog, translation efficiency was twice more than in rabbit reticulocyte lysate (Stepinski et al. 2001).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
What the sources say
- Not checked — no full text of the sourcecites Stepinski et al. 2001
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“This effect can be achieved by inserting AU-rich regions into 3′-UTRs ensuring fast mRNA breakdown and a short duration of protein expression (Chen and Shyu 1995).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
What the sources say
- Not checked — no full text of the sourcecites Chen and Shyu 1995 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The 5′ cap regulates pre-mRNA splicing and nuclear export, works as a protective structure that shields RNA from exonuclease cleavage, and initiates mRNA translation.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Several studies have linked the length of the poly(A) tail to translation efficiency (Conry et al. 1995).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Not matchedcites Conry et al. 1995
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“(ii) Ribosome recruitment and codon recognition can be prevented by avoiding the existence of highly stable secondary structures”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Modifying the mRNA structural elements particularly the 5′ cap, 5′-and 3′-untranslated regions (UTRs), the coding region, and polyadenylation tail help reduce the excessive mRNA immunogenicity and consistently improve its intracellular stability and translational efficiency.”
- Also stated in: § Introduction · plain
“This review discussed the iterative optimization and significant modifications of the mRNA structure particularly the 5′ cap, 5′ and 3′UTRs, the coding region, and the poly(A) tail which improve the stability, translation capacity and increase the efficacy of mRNA vaccines to trigger the immune response.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Abstract > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“For mRNA stability and efficient translation, mRNA undergo post-transcriptional changes such as 5′-capping and poly(A).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“By interacting with RNA-binding proteins, UTRs can also influence the rate of mRNA degradation and translation efficiency.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Using enzymes to cap the 5′ terminus of mRNA is more efficient than using cap analogs such as 7-methylguanosine (Jani and Fuchs 2012; Urbina and Morales-Pison 1633).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Not matchedcites Jani and Fuchs 2012
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites Urbina and Morales-Pison 1633
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The most prevalent ARCA enables only the insertion of a nucleotide at the non-methylated guanosine after 3′-O-methylation of base-methylated guanosine.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The translational elongation rate and efficiency are also affected by the neighboring nucleotides and codons (Bossi and Ruth 1980).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Not checked — no full text of the sourcecites Bossi and Ruth 1980 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mRNA sequence codon optimization can significantly impact the protein production rate and ribosome bide time.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“A functional 5′ cap structure is required for robust mRNA translation.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The cap 0 structure of m7GpppN is necessary for effective mRNA translation.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Kormann et al., demonstrated that 2 weeks following injection of nucleoside-modified mRNA containing 25% thio-uridine and 25% 5-methylcytidine resulted in Epo levels five times greater than that in untreated animals.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Not checked — no full text of the sourcecites Kormann et al. 2011 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Cap and poly(A) tail located at the 5′- and 3′-ends of mRNA are critical for stability of mRNA in the cytosol.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The mRNA structure, translational efficiency, and protein-folding machinery are most likely to be altered by substituting the mRNA sequence with rare codons and inserting modified nucleotides (Zhong et al. 2017).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Not checked — no full text of the sourcecites Zhong et al. 2017 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The employment of “anti-reverse” cap analogs results in a cap that is in the correct orientation Anti-Reverse Cap Analog (ARCAs).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 5′ UTR sequence can be adjusted to improve mRNA stability and translation accuracy by (i) avoiding the presence of start codons and non-canonical start codons in the 5′ UTR which disrupts ORF translation”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Furthermore, distinct areas of cellular and viral 5ʹ- and 3ʹ-UTRs improve mRNA stability and efficiency of translation.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“mRNA also need 5′ and 3′ UTRs around the open reading frame (ORF) to increase half-life, vaccine mRNA expression levels, and translation (Conry et al. 1995).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Not matchedcites Conry et al. 1995
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 5′-UTR/3′-UTR, 5′ cap, the poly(A) tail, a rare codon and G:C content can be optimized to improve mRNA stability.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The intensity and specificity of the immune responses are expected to be influenced by these changes.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: The intensity and specificity of the immune responses are influenced by changes in mRNA structure, translational efficiency, and protein-folding machinery.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Chemically altering nucleotides, adding poly(A) tails, and optimizing mRNA with a GC-rich sequence are efficient ways to minimize mRNA immunogenicity.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Eliminating mRNA immunogenicity
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Chemically altering nucleotides, adding poly(A) tails, and optimizing mRNA with a GC-rich sequence are efficient ways to minimize mRNA immunogenicity.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Eliminating mRNA immunogenicity
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mRNA purification is also required after IVT to eliminate immunogenicity.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Eliminating mRNA immunogenicity
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Storing and transferring mRNA vaccines to and from warm countries is thus a major technical and financial challenge.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Chemically altering nucleotides, adding poly(A) tails, and optimizing mRNA with a GC-rich sequence are efficient ways to minimize mRNA immunogenicity.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Eliminating mRNA immunogenicity
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The COVID-19 mRNA vaccine highlight that using structurally modified mRNA allows for increased dose tolerance and may be better for eliciting a rapid antibody response.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Conclusion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The COVID-19 mRNA vaccine highlight that using structurally modified mRNA allows for increased dose tolerance and may be better for eliciting a rapid antibody response.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Conclusion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
In the paper
“5-methylcytidine (m5C), and pseudouridine (ψ) are the most preferred base-pair alterations because they lower immunogenicity while increasing translation efficiency (Weng 2020).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Eliminating mRNA immunogenicity
What the sources say
- Not checked — no full text of the sourcecites Weng 2020 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Because antigen translation occurs in the cytoplasm rather than the nucleus; therefore mRNA vaccines have a greater biosafety than DNA vaccines as their antigens are translated into the cytoplasm rather than the nucleus, making it more difficult for the mRNA to integrate into the genome.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As soon as the sequence encoding the immunogen is available, RNA synthesis may begin on the same platform.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 28
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The bulk of the mRNA vaccines reported till date have an m7GpppNm cap inserted at the 5′-end during IVT (Corbett et al. 2020).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
What the sources say
- Partly supportedcites Corbett et al. 2020 sourceExperimental — accuracy not yet measured
The Methods section (Pre-clinical mRNA-1273 mRNA and LNP Production Process; page unavailable) says this vaccine’s mRNA was made by in vitro transcription and received a 5′ Cap 1 structure. It specifies that the cap was added after transcription, not during it, and does not establish what the bulk of reported mRNA vaccines use. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The findings revealed that mice administered mRNA-LNP produced protective antibodies, assisting them in overcoming HIV-1 infection (Pardi et al. 2017).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Partly supportedcites Pardi et al. 2017 sourceExperimental — accuracy not yet measured
The Results section reports that VRC01 mRNA-LNPs produced antibodies in humanized mice and protected them when administered before HIV-1 challenge. It does not show mice overcoming an established infection. The Methods also specify FPLC purification, not the HPLC purification stated in the supplied paraphrase. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For appropriate folding, some proteins require delayed translation, which is guaranteed by uncommon codons (Kimchi-Sarfaty et al. 2007).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Partly supportedcites Kimchi-Sarfaty et al. 2007 sourceExperimental — accuracy not yet measured
The paper’s opening summary (section labeled “1 (”, page unavailable) hypothesizes that a rare codon affects the timing of cotranslational folding of P-glycoprotein. It does not establish that uncommon codons guarantee delayed translation or that some proteins require such a delay for appropriate folding; the citing sentence presents a proposed mechanism as a general fact. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The modified nucleosides escape the type interferons (IFNs) induced antiviral pathways and are targeted to break and block invading mRNA; therefore they can be used to create mRNA vaccines with significantly improved translation efficiency (Verbeke et al. 2019).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Supportedcites Verbeke et al. 2019 source
Section 2.3 states that modified nucleosides allow mRNA vaccines to avoid type I IFN-induced antiviral pathways that degrade or inhibit invading mRNA, thereby improving stability and translation capacity. The source describes the pathways—not the modified nucleosides—as targeting invading mRNA. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“mRNA transcripts containing modified nucleosides, also known as nucleoside-modified mRNAs, are created with lower immunostimulatory activity and a better safety profile.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Supportedcites Verbeke et al. 2019 source
Section 2.3 explicitly says that incorporating modified nucleosides produces transcripts called “nucleoside-modified mRNA” with reduced immunostimulatory activity and, consequently, an improved safety profile. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The poly(A) tail steadies mRNA and boosts protein translation, and the length of the poly(A) tail is proportional to translation efficiency.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > The poly(A) tail
What the sources say
- Supportedcites Park et al. 2016 source
The Introduction describes the poly(A) tail as important for mRNA stability and translational regulation, and the Abstract calls poly(A) tails critical for both. This supports the quoted claim. The paper separately limits the relationship between tail length and translation efficiency to short tails; that relationship is not part of the quoted claim. (LLM, conf=0.92)
- Supportedcites Jalkanen et al. 2014 source
The Introduction says poly(A) tails enhance translation efficiency and that tail shortening is a key step initiating mRNA decay. The section on cytoplasmic factors also describes poly(A)-tail-associated proteins that increase mRNA stability. These passages support the attributed claim; page numbers are not provided in our copy. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The mRNA also does not interact with the genome and only the parts directly required for the encoded protein expression are present in this basic genetic construct (Pardi et al. 2018).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Supportedcites Pardi et al. 2018 source
The Safety section says that integration into host-cell DNA is not a concern for mRNA, supporting the claim about the genome. Basic mRNA vaccine pharmacology describes conventional mRNA constructs as containing the protein-coding sequence, untranslated regions, a 5′ cap and a poly(A) tail; it contrasts these with self-amplifying RNA, which also encodes viral replication machinery. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“mRNA is created via a cell-free enzymatic transcription reaction that enables rapid and scalable production, as illustrated by the current pandemic's rapid pursuit of RNA vaccines (Verbeke et al. 2021).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Partly supportedcites Verbeke et al. 2021 sourceExperimental — accuracy not yet measured
In “COVID-19 creates momentum for mRNA vaccines” (page unavailable), the paper discusses in vitro-transcribed (IVT) mRNA, and “Conclusions and perspectives” describes exceptionally rapid development and production of COVID-19 mRNA vaccines. It does not explicitly describe a cell-free enzymatic transcription reaction; the scalable production system it identifies is microfluidic mixing to formulate mRNA-loaded nanoparticles, not transcription itself. (LLM, conf=0.82)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“They comprise various regulatory regions related to mRNA stability, ribosome recognition, interaction with translational machinery components, and mRNA secondary structures (Tanguay and Gallie 1996).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
What the sources say
- Partly supportedcites Tanguay and Gallie 1996 sourceExperimental — accuracy not yet measured
The introduction describes 3′ UTR elements that regulate mRNA stability and translation, and the Discussion describes interactions with initiation factors and ribosomal machinery. The references identify stem-loops and pseudoknots in untranslated regions, but the paper does not clearly establish the claim about ribosome recognition. Its direct analysis also concerns 3′ UTRs, rather than UTRs generally. (LLM, conf=0.84)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The basic structure of mRNA, same as eukaryotic mRNA, is made up of (i) protein encoding ORF, surrounded by (ii) 5′ and 3′ UTRs, and (iii) a 7-methyl guanosine 5′ cap structure and (iv) a 3′poly(A) tail at the end sides (Verbeke et al. 2019; Schlake et al. 2012; Sahin et al. 2014) (Fig. 1).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > mRNA structural elements design and modifications
What the sources say
- Supportedcites Verbeke et al. 2019 source
Section 2.3 states that IVT mRNA closely resembles mature eukaryotic mRNA and lists the same four structural features: a protein-encoding ORF, flanking 5′ and 3′ UTRs, a 7-methyl guanosine 5′ cap, and a 3′ poly(A) tail. (LLM, conf=0.95)
- Supportedcites Schlake et al. 2012 source
The mRNA Design section describes synthetic mRNA as following the blueprint of eukaryotic mRNA. It identifies a protein-encoding ORF flanked by 5′ and 3′ UTRs, a 7-methyl-guanosine cap at the 5′ end, and a poly(A) tail at the 3′ end. (LLM, conf=0.94)
- Supportedcites Sahin et al. 2014 source
The Figure 2 caption identifies the cap, 5′ and 3′ UTRs, ORF, and poly(A) tail as components of the mRNA. The section “The 5′ cap” specifies that natural eukaryotic mRNA has a 7-methylguanosine cap. Together, these passages support the attributed structural description. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“N1-methyl-pseudouridine (1mΨ) nucleotide substitution has been found to increase base pair stability, resulting in complex secondary structure and improved mRNA translation (Mauger et al. 2019).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Partly supportedcites Mauger et al. 2019 sourceExperimental — accuracy not yet measured
The Discussion reports that m1Ψ stabilizes base pairing and mRNA secondary structure and generally increases protein output. But the Results section, “Codon Usage and mRNA Structure Synergize to Determine Ribosome Loading and mRNA Half-Life,” finds that protein output correlates poorly with translation rate and strongly with functional mRNA half-life. Thus the structural and protein-output parts are supported, but “improved mRNA translation” overstates the measured mechanism. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The 7-methylguanosine (m7G) moiety is found at the 5′ end of natural mRNA in the eukaryotic cytoplasm, followed by a triphosphate connection to the first nucleotide (m7GpppN) (Sahin et al. 2014).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
What the sources say
- Supportedcites Sahin et al. 2014 source
The “5′ cap” section states that natural eukaryotic mRNA has a 7-methylguanosine cap linked by a 5′–5′ triphosphate bridge, yielding the m7GpppN structure. This supports the attributed description of the cap at the 5′ end. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BNT162b2 includes N1-methylpseudouridine, optimized codon; high GC sequence, removed dsRNA, and N1-methylpseudouridine modifications (Polack et al. 2020).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
What the sources say
- Partly supportedcites Polack et al. 2020 sourceExperimental — accuracy not yet measured
The Abstract Methods identifies BNT162b2 as a nucleoside-modified RNA vaccine, supporting the general modification claim. Our copy does not specify N1-methylpseudouridine, codon optimization, high GC content, or removal of double-stranded RNA; searches for those terms found no supporting passage. Page numbers were not available in our copy. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The COVID-19 vaccine candidates demonstrate the structurally modified mRNA approach allows for higher tolerated doses and may be more suitable for producing a fast antibody response (Verbeke et al. 2021).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
What the sources say
- Supportedcites Verbeke et al. 2021 source
The Conclusions and perspectives section says the COVID-19 case suggests that nucleoside-modified mRNA permits higher maximal tolerable doses and might be better suited to rapidly generating antibody responses. It cautions that direct comparisons between vaccine candidates require care; the citing sentence preserves the uncertainty about antibody responses. (LLM, conf=0.90)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, 5′ UTR: human -globin RNA with optimized Kozak sequence, 3′ UTR: AES and mtRNR1 3′ UTR Motives, and 110 Poly(A) tail with nucleotide-linker (GCAUAUGACU) are also used (Orlandini von Niessen et al. 2019).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
What the sources say
- Partly supportedcites Orlandini von Niessen et al. 2019 sourceExperimental — accuracy not yet measured
The Results (page unavailable) describe AES and mtRNR1 motifs combined in experimental mRNA 3′ UTRs, supporting that component of the description. The paper does not identify BNT162b2 or establish its 5′ UTR, optimized Kozak sequence, or specified 110-adenosine tail and linker. Its Results instead describe a reporter with a 60-adenosine tail, which does not determine BNT162b2’s composition. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The technique can be easily scaled requiring minimum platform changes during mRNA formulation and production (Pardi et al. 2018).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
What the sources say
- Partly supportedcites Pardi et al. 2018 sourceExperimental — accuracy not yet measured
The Good manufacturing practice production section (page not provided) describes mRNA manufacturing as sequence-independent and largely standardized, supporting scalability with limited production-process changes. It does not establish that formulation likewise requires minimal platform changes; it describes pharmaceutical formulation as an active area of development. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Moderna on the other hand used N1-methylpseudouridine, removed dsRNA, and undisclosed structural elements (Baden et al. 2021) (Fig. 2A).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
What the sources say
- Could not verifycites Baden et al. 2021 sourceExperimental — accuracy not yet measured
The Background (p. 1) describes mRNA-1273 as an mRNA vaccine encoding a stabilized spike protein, but does not specify its nucleoside modifications or manufacturing steps. Searches for N1-methylpseudouridine, dsRNA removal, and structural elements found no passage in our copy addressing those claims. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The extraction of neutralizing antibodies from COVID-19 patient’s serum verified the S protein’s high immunogenicity, whereas the receptor binding domain (RBD) and N-terminal domains were also equally immunogenic (NTD).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
What the sources say
- Partly supportedcites Liu et al. 2020 sourceExperimental — accuracy not yet measured
The opening summary (p. 1) reports neutralizing antibodies from five COVID-19 patients and says the potent antibodies were about equally divided between RBD and NTD targets, indicating that both spike regions are immunogenic. But “Isolation and construction of mAbs” (p. 2) describes sorting spike-binding memory B cells from blood and producing monoclonal antibodies from their sequences, not extracting antibodies from patient serum. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Protein-based vaccinations are usually made from bacteria, however mRNA vaccines can be produced by the host translation machinery, resulting in an antigen that closely resembles the structure of the protein released from the viral genome (Park et al. 2021).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
What the sources say
- Supportedcites Park et al. 2021 source
The section “Advantages and disadvantages of mRNA vaccines over other vaccine platforms” directly states that protein-based vaccines are often produced from bacteria, while mRNA vaccines use host translation machinery to form an antigen likely to mimic the structure of the protein expressed from the viral genome. The citing sentence preserves that qualified comparison. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Poly(A) tails of approximately 100 nt are ideal for synthesizing mRNA therapies because tail size affects mRNA decay by modulating 3′ exonucleolytic degradation (Schlake et al. 2012).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > The poly(A) tail
What the sources say
- Partly supportedcites Schlake et al. 2012 sourceExperimental — accuracy not yet measured
The Poly(A) tail section reports that tail length affects protein expression, but its results vary by cell type and do not establish approximately 100 nucleotides as ideal. The mRNA Design section says poly(A) tails help stabilize mRNA where decay is predominantly catalyzed by exonucleases; it does not say tail size modulates 3′ exonucleolytic degradation. Page numbers were unavailable in our copy. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Eliminating mRNA immunogenicity
What the sources say
- Supportedcites Sahin et al. 2014 source
The Conclusions and perspectives section states that IVT mRNA can be manufactured at relatively low cost. The Principal concept of mRNA pharmacology section explains that the mRNA is synthesized by in vitro transcription, supporting the claim that IVT is a low-cost synthesis method. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
In the paper
“The basic concept underlying mRNA vaccines is to encode the antigen in mRNA and transfer the transcript to the host cell’s cytoplasm via a non-viral delivery route, permitting antigen expression and stimulation of an antigen-specific immune response (Jackson et al. 2020).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Introduction
What the sources say
- Not matchedcites Jackson et al. 2020
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Destabilizing mRNA may be useful in some applications to reduce the time required for protein synthesis.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“5′-UTR regulatory elements and the length of the 3′-UTR aid translation of protein.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ- and 3ʹ-UTRs
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“5-methylcytidine (m5C) and pseudouridine (ψ) nucleotide modifications are commonly preferred in base-pair alterations as they lower immunogenicity while increasing the efficiency of translation (Weng 2020).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Not checked — no full text of the sourcecites Weng 2020 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The 5′ cap regulates pre-mRNA splicing and nuclear export, works as a protective structure that shields RNA from exonuclease cleavage, and initiates mRNA translation.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Unmodified mRNA, on the other hand, showed no significant alterations and merely elicited a considerable immunological response (Kormann et al. 2011).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Not checked — no full text of the sourcecites Kormann et al. 2011 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The translation and stability of mRNA can be improved and critical tasks have been undertaken to identify desirable mRNA elements.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > mRNA structural elements design and modifications
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“ARCA-capped mRNA has been shown to boost and extend protein expression in cultured cells (Zohra et al. 2007).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > 5ʹ-capping of mRNA vaccines
What the sources say
- Not checked — no full text of the sourcecites Zohra et al. 2007 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Translation efficiency, mRNA abundance, and protein folding may all be affected by codon optimization.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These components can be modified or altered to increase the stability, translation efficiency, and immune-stimulatory feature of mRNA (Table 1).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > mRNA structural elements design and modifications
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The start codon should include Kozak sequence (Kozak 1986), and the stop codon's sequence can be modified (Liu 2005).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Open reading frame (ORF)
What the sources say
- Not checked — no full text of the sourcecites Kozak 1986 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Optimizing the mRNA structural features particularly the 5′ cap, 5′ and 3′UTRs, the coding region, and the poly(A) tail increases the mRNA’s control of immune responses resulting in higher translational efficiency.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Conclusion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The efficacy of both the mRNA vaccines is more than 90% (~ 95% to be precise).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Modifying or improving the structural features can boost the mRNA’s potential to control innate immune responses, resulting in increased translation capacity and bioavailability.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Future perspective
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Despite the advantages of mRNA vaccines there are still many risks involved such as long term effects of the mRNA vaccine are unknown.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mRNA vaccines provide flexibility in development as any protein can be made from mRNA without changing the production or application procedure.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Conclusion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Spike proteins with K986P, V987P substitutions are common in both vaccines.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The final result can be dramatically improved by optimizing the structure of mRNA.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Future perspective
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Enzymatic polyadenylation has the disadvantage of having a variety of RNA species with variable poly(A) tail lengths in each RNA preparation.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > The poly(A) tail
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Furthermore, mRNA is a transient molecule carries a short translation sequence it has no interaction with the host genome.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Vaccine development often requires years of research and testing to ensure efficacy and safety.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“HPLC, anion exchange and affinity chromatography, are used in the purification process to remove truncated transcripts (Weissman et al. 2013).”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Eliminating mRNA immunogenicity
What the sources say
- Not checked — no full text of the sourcecites Weissman et al. 2013 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The COVID-19 pandemic has increased the interest in mRNA vaccinations.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“mRNA vaccines work on the principle of delivering a transcript that encodes a target antigen or immunogen.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Contrarily, in vitro transcription (IVT) of RNA from a DNA template produces RNA with a predetermined poly(A) tail length, which is preferable, particularly for clinical purposes.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > The poly(A) tail
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Because antigen translation occurs in the cytoplasm rather than the nucleus; therefore mRNA vaccines have a greater biosafety than DNA vaccines as their antigens are translated into the cytoplasm rather than the nucleus, making it more difficult for the mRNA to integrate into the genome.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Adding poly(A) tails lowers mRNA immunogenicity by lowering U content and shielding mRNA in the sequence.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Eliminating mRNA immunogenicity
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Because of the ease and speed with which mRNA vaccines may be produced, they are often favored over alternative platforms.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In contrast, the two mRNA vaccines took less than a year to develop and deploy from start to finish.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Their rapid creation, manufacture, and excellent effectiveness in preventing SARS-CoV-2 infection, show that mRNA-based therapies are ready for application in the future.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > COVID-19 mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“After transfection, mRNA vaccine expresses the protein target (antigen) via translation from mRNA.”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper relies on this without support.
mRNA is susceptible to degradation and stabilizing it may lead to high expression.
“The mRNA is susceptible to degradation and stabilizing it may lead to high expression.”
The paper relies on this without support.
The intensity and specificity of the immune responses are influenced by changes in mRNA structure, translational efficiency, and protein-folding machinery.
“The intensity and specificity of the immune responses are expected to be influenced by these changes.”
The paper relies on this without support.
mRNA is unstable and must be stored at high temperature, making packaging and distribution of vaccine difficult.
“mRNA is also unstable and must be stored at high temperature making packaging and distribution of vaccine difficult.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is known that UTRs are associated with processes of mRNA translation, and by interacting with RNA-binding proteins (RBPs) and microRNAs, UTRs can influence mRNA’s translation efficiency and resistance to degradation [3,4,5,6,7].”
From Untranslated Region Sequences and the Efficacy of mRNA Vaccines against Tuberculosis (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For mRNA vaccine, modifying the structural elements of mRNA including the 5′ cap, 5′-and 3′-untranslated regions, the coding region, and polyadenylation tail help improved the intracellular stability of mRNA (55).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
“mRNA vaccines must be stored and carried at extremely low temperatures”
§ Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency > Advantages of mRNA vaccines
“mRNA is also unstable and must be stored at high temperature making packaging and distribution of vaccine difficult.”
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Kozak, M. (1986) · Cell · doi:10.1016/0092-8674(86)90762-2 · Cited by 4,741
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
AU-rich elements: characterization and importance in mRNA degradation
Chen, C.-Y. A., & Shyu, A.-B. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89102-1 · Cited by 1,948
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Cited by
Sorted by citations
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 909
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Parhiz, H., Atochina‐Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 303
mRNA vaccines for cancer immunotherapy
Vishweshwaraiah, Y. L., & Dokholyan, N. V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029069 · Cited by 184
Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines
Kim, B., Hosn, R. R., Remba, T. K., Yun, D. S., Li, N., Abraham, W. D., Melo, M. B., Cortés, M., Li, B., Zhang, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.022 · Cited by 157
mRNA vaccine in cancer therapy: Current advance and future outlook
Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 158
Metadata
- Authors
- Kim, S. C., Sekhon, S. S., Shin, W.-R., Ahn, G., Cho, B.-K., Ahn, J.-Y., & Kim, Y.-H.
- Affiliations
- Korea Advanced Institute of Science and Technology (KR)
- Chungbuk National University (KR)
- Corresponding author
- Kim, Yang-Hoon
- Venue
- Molecular & Cellular Toxicology
- Published
- 2021-09-20
- Volume
- 18
- Issue
- 1
- Pages
- 1-8
- ISSN
- 1738-642X (ISSN-L)
- 2092-8467
- PMC
- PMC8450916
- OpenAlex
- W3201215980
- Cited by
- 255
- References
- 57
- Citations by year
- 2026: 38 · 2025: 79 · 2024: 68 · 2023: 46 · 2022: 22 · 2021: 1
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Molecular & Cellular Toxicology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- national research foundation of korea (2020R1A6A1A06046235, 2019R1A2C1010860)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- mRNA vaccines, mRNA stability, translation efficiency, 5' cap, 5' untranslated region, 3' untranslated region, polyadenylation, vaccine optimization, viral infection therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review